Circulating soluble LOX-1 and patient prognosis after an acute coronary syndrome
Authors' conclusion
Elevated plasma sLOX-1 at baseline and during follow-up is associated with incident HF and MACE, as well as cardiac and coronary dysfunction in patients with ACS. As plasma sLOX-1 levels may reflect the intensity of LOX-1 expression on vascular and immune cells, these findings support LOX-1 as a potentially important therapeutic target to improve prognosis in patients with ACS.
Study context
- Population
- Patients with acute coronary syndrome (ACS)two cohorts · First cohort (Skåne University Hospital, Malmö) 524 · Second cohort (Sahlgrenska University Hospital, Gothenburg) 363
- Exposure
- Plasma sLOX-1 (per 1-SD increase) and development of heart failure (HF), major adverse cardiovascular events (MACE) and coronary and left ventricular (LV) dysfunction
- Outcome
- Incident HF and MACE (first cohort)
Methodological detailstwo cohorts, in vitro experiments using human umbilical vein endothelial cells (HUVECs)
- Two cohorts
- In vitro experiments using HUVECs
Main finding
As reported in the abstract
Per 1-SD sLOX-1 increase, as printed
Observational data: associations, not effects.
Further findings
LV ejection fraction and remodelling by echocardiography (first cohort) · 1-year post-ACS
- Elevated sLOX-1 associated with lower LV ejection fraction and accelerated remodelling
Coronary flow reserve, LV systolic function, markers of inflammation and cardiac overload (second cohort) · 4 and 16 weeks post-ACS
- sLOX-1 negatively associated with left anterior descending coronary artery flow reserve and LV systolic function
- sLOX-1 positively correlated with soluble markers of systemic inflammation and cardiac overload
HUVEC activation in vitro
- Antibody-mediated LOX-1 blockade prevented oxidised low-density lipoprotein-induced HUVEC activation
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →